January 27, 2026
DARZALEX FASPRO®-based Quadruplet Regimen approved in the U.S. for newly Diagnosed patients with multiple Myeloma who are Transplant Ineligible
No current content.
At Johnson & Johnson Innovative Medicine, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Contract Research & Scientific Services

January 27, 2026
No current content.